Comparison of Upper Extremity Exercise Capacity and ADL Between Subjects With Bronchiectasis and Healthy Controls

Bronchiectasis Clinical Trial

Official title:

A Comparison of Upper Extremity Exercise Capacity and Activities of Daily Living Between Subjects With Bronchiectasis and Healthy Controls

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05084547
• Other study ID #: GO 20/55
• Status: Completed
• Start date: January 22, 2020
• Est. completion date: December 22, 2022

Study information

• Verified date: January 2023
• Source: Hacettepe University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Bronchiectasis is a chronic lung disease characterized by permanent dilatation and destruction, resulting from the destruction of elastic tissue and muscular components in the bronchial walls, due to infection or inflammation. The exercise tolerance, physical activity level, respiratory and peripheral muscle strength of patients with bronchiectasis are lower than those of healthy individuals. The decrease in exercise tolerance occurs while performing upper extremity activities as well as lower extremity tasks. Many studies have reported that upper extremity exercise capacity is reduced in chronic obstructive pulmonary disease (COPD), a disease similar to bronchiectasis, and that patients often experience significant dyspnea and fatigue during upper extremity tasks that are important for daily life. The mechanisms causing this situation may be neuromechanical dysfunction of the respiratory muscles (diaphragm and accessory respiratory muscles) (thoracoabdominal asynchrony) and changes in lung volume in activities involving the upper extremities. The disturbances in ventilatory mechanics in patients with COPD cause upper extremity exercise to be terminated at low workloads compared to healthy individuals. Upper extremity exercise has been defined as part of pulmonary rehabilitation. The determination of upper extremity exercise capacity may play a predictive role in maintaining and improving upper extremity and daily life activity level in patients with chronic lung disease.

Six-minute Pegboard and Ring test (6PBRT) is used to evaluate extremity exercise capacity and upper extremity function and endurance. The 6PBRT score and upper extremity daily living activities show a clear relationship in patients with COPD, and it can be used to determine and improve the performance of daily living activities in pulmonary rehabilitation programs. Glittre Activities of Daily Living (Glittre ADL test) covers activities that are necessary for daily living and commonly used activities. The Glittre ADL test produces similar cardiorespiratory responses when compared with the six-minute walk test. In this study, unsupported upper extremity exercise capacity and upper extremity function/endurance and the performance of daily living activities will be compared in participants with bronchiectasis and compared with healthy individuals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: December 22, 2022
• Est. primary completion date: December 22, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with bronchiectasis and being clinically stable,

• Being 18 years old or older,

• Being able and willing to complete the informed consent process.

Exclusion criteria:

• Individuals with bronchiectasis whose clinical condition is unstable,

• Individuals with bronchiectasis who have severe neuromuscular, musculoskeletal, and rheumatological problems,

• Being unable to cooperate,

• Not being willing to participate in the study

The healthy controls will be composed of individuals who volunteered for the study without any known disease. Healthy individuals who did not volunteer to participate in the study will not be included.

Related Conditions & MeSH terms

• Bronchiectasis

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
Turkey	Hacettepe University	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulmonary function test - Forced vital capacity	Pulmonary function test using a spirometer will be performed. Forced vital capacity will be recorded.	1st day
Primary	Pulmonary function test - Forced expiratory volume in one second	Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second will be recorded.	1st day
Primary	Pulmonary function test - Forced expiratory volume in one second/Forced vital capacity	Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second/Forced vital capacity in one second will be recorded.	1st day
Primary	Pulmonary function test - Peak expiratory flow	Pulmonary function test using a spirometer will be performed. Peak expiratory flow will be recorded.	1st day
Primary	Pulmonary function test - Forced mid-expiratory flow (FEF25-75)	Pulmonary function test using a spirometer will be performed. Forced mid-expiratory flow (FEF25-75) will be recorded.	1st day
Primary	Glittre Activities of Daily Living Test	The test covers activities that are necessary for daily living and commonly used activities that are known to be difficult for patients with COPD.	1st day
Primary	Unsupported upper extremity exercise capacity	Upper extremity exercise capacity will be evaluated using 6PBRT. During the test, the patient is asked to sit in front of a pegboard and move as many rings as possible from the two lower holes to the two upper holes, using both hands simultaneously, for six minutes. The number of rings carried during the six minutes constitutes the final score. Heart rate and oxygen saturation with pulse oximetry before and after the test, dyspnea, arm and general fatigue will be assessed.	1st day